EBP

3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase · Q15125 · EBP on Sugi Atlas →

23,495 patent compounds predicted against EBP, 15,512 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Cycloartanol (SCHEMBL455049)	0.52	8/20
Cycloartanol (SCHEMBL455050)	0.52	8/20
SCHEMBL133391	0.50	7/20
Enclomiphene (SCHEMBL34893)	1.00	6/20
Zuclomiphene (SCHEMBL34894)	1.00	6/20
Zuclomiphene (SCHEMBL402392)	0.97	6/20
Enclomiphene (SCHEMBL407458)	0.97	6/20
Enclomiphene (SCHEMBL220459)	0.75	5/20
Clomiphene (SCHEMBL220953)	0.75	5/20
Zuclomiphene (SCHEMBL223472)	0.75	5/20
Clomiphene (SCHEMBL220954)	0.71	5/20
SCHEMBL906173	0.69	5/20
SCHEMBL906174	0.69	5/20
SCHEMBL640570	0.58	5/20
SCHEMBL640174	0.52	5/20
SCHEMBL332666	0.50	5/20
Hydrochloric Acid (SCHEMBL641578)	0.39	5/20
Triparanol (SCHEMBL133384)	1.00	4/20
SCHEMBL330094	0.67	4/20
SCHEMBL1152819	0.65	4/20

Clinical trials — most relevant to EBP by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Mechanisms of Lipodystrophy in HIV-Infected Pateints	PHASE4	COMPLETED
Effects of Ipragliflozin on Excessive Fat in Type 2 Diabetes Patients With Non-alcoholic Fatty Liver Disease Treated With Metformin and Pioglitazone	PHASE4	COMPLETED
Efficacy Study of Pioglitazone Compared to Glimepiride on Coronary Atherosclerotic Disease Progression in Subjects With Type 2 Diabetes Mellitus	PHASE3	COMPLETED
A Study of Bezafibrate in Mitochondrial Myopathy	PHASE2	COMPLETED
Efficacy and Safety of Oltipraz in the Patients With Liver Fibrosis and Cirrhosis	PHASE2	COMPLETED
Comparative Study Between Obeticholic Acid Versus Vitamin E in Patients with Non-alcoholic Steatohepatitis	PHASE2	ACTIVE_NOT_RECRUITING
A Clinical Trial for the Safety and Efficacy of CD-801 in Patients With Advanced Hepatocellular Carcinoma	EARLY_PHASE1	COMPLETED
A Case Control Study of Resveratrol Effects in Coronary Artery Disease Patients With Metabolic Syndrome	nan	COMPLETED
Vitamin D Status in Inflammatory Bowel Disease	nan	UNKNOWN
The Role of Programmed Death Ligand -1 (Pdl-1) in Lung Cancer	nan	COMPLETED
Assessing the Effects of Alfacalcidol Intake on Expression of Involed Gene in Metabolism in Obese Subjects	nan	UNKNOWN
Fish Oil and Nonalcoholic Fatty Liver Disease (NAFLD) Study	nan	COMPLETED
The Effect of Dietary Fat Load and Physical Exercise on the Flexibility and Partitioning of Ectopic Lipids.	nan	COMPLETED
Hypovitaminosis D and Metabolic Inflammatory Status in Patients With Obesity	nan	COMPLETED
Relation Between NAFLD and BM DENSITY	nan	NOT_YET_RECRUITING
Can Dietary Phytoestrogens Slow Down Prostate Tumor Proliferation?	nan	UNKNOWN
Immunolocalization of 1,25,Dihydroxyvitamin D3 in Aggressive Periodontitis Patients	nan	COMPLETED
Sexual Hormones and Haemostasis: Observations for Women Health	nan	UNKNOWN
Association of SGLT2 Inhibitors Therapy With Elastographic and Molecular Markers of Liver Injury in Type 2 Diabetes	nan	COMPLETED
Normal Serum Adiponectin Levels in Females	nan	UNKNOWN
Polycystic Ovary Syndrome in Type 1 Diabetes	nan	NOT_YET_RECRUITING
Clinical Study to Evaluate Safety and Efficacy of Amino Acid in Healthy Individuals	nan	COMPLETED
Progression and Etiology of Cortical Porosity in Diabetic Bone Disease	nan	COMPLETED
Evaluation of the Predictive Effect of Inflammatory Markers in MI Patients	nan	UNKNOWN
Effect of SGLT2 Inhibitors on NAFLD in Type 2 Diabetic Patients with Diabetic Nephropathy	nan	NOT_YET_RECRUITING
Effects of Losartan on Insulin Sensitivity and Secretion in Type 2 Diabetes and Nephropathy	nan	COMPLETED
RORC Genetic Polymorphism of Rheumatoid Arthritis	nan	COMPLETED
Visualizing Beta Cells in Patients With a History of Gestational Diabetes	nan	UNKNOWN
Effects of Gallotannins on the Gut Microbiome and How it Affects Inflammatory Markers Among Obese Individuals.	nan	ACTIVE_NOT_RECRUITING
Impact Of Choline in Patients With NAFLD	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a EBP binder may also engage these)

Protein	Name	Similarity
P70245	—	1.000	P70245 →
Q9JJ46	—	0.999	Q9JJ46 →
Q60490	—	0.999	Q60490 →
Q8VD00	—	0.982	Q8VD00 →
O48962	—	0.981	O48962 →
A0A067DFU5	—	0.980	A0A067DFU5 →
P0DXH1	—	0.980	P0DXH1 →
A0A9Y1LQX3	—	0.979	A0A9Y1LQX3 →
Q2U6A4	—	0.979	Q2U6A4 →
Q0V982	—	0.979	Q0V982 →
Q2U0S9	—	0.979	Q2U0S9 →
Q9BZW4	—	0.979	Q9BZW4 →
Q5AXD1	—	0.978	Q5AXD1 →
A0A067E3D8	—	0.978	A0A067E3D8 →
Q4WVG2	—	0.978	Q4WVG2 →
Q4W9R7	—	0.978	Q4W9R7 →
Q4WJJ9	—	0.977	Q4WJJ9 →
J7FIJ6	—	0.977	J7FIJ6 →
P36209	—	0.977	P36209 →
Q7ZXH1	—	0.976	Q7ZXH1 →
Q6DFQ5	—	0.976	Q6DFQ5 →
Q6DCP8	—	0.976	Q6DCP8 →
Q5R8F1	—	0.976	Q5R8F1 →
Q5Z413	—	0.976	Q5Z413 →
Q9W5D4	—	0.976	Q9W5D4 →
O13113	—	0.976	O13113 →
O15321	—	0.975	O15321 →
DHCR7	7-dehydrocholesterol reductase	0.975	landscape →
Q5R7H4	—	0.975	Q5R7H4 →
B0D4E6	—	0.975	B0D4E6 →